A June 2026 JAMA Health Forum analysis of biosimilar regulations across 19 countries reveals persistent divergence in approval standards, substitution policies, and reliance on foreign data—directly constraining supply of lower-cost GLP-1 agonists such as semaglutide biosimilars. This observational policy-mapping study (no randomization, n=19 regulatory jurisdictions) identifies that nations requiring local patient trials or prohibiting pharmacy-level substitution face delayed market entry averaging 18–36 months compared with harmonized regions. The UCSF team, led by Jonathan Watanabe, notes that biologics already account for over half of U.S. drug spending despite comprising only 5% of prescriptions; similar cost burdens now limit GLP-1 access in low- and middle-income settings where diabetes prevalence exceeds 10%. Regulatory fragmentation echoes earlier small-molecule generic delays pre-1984 Hatch-Waxman Act, yet no equivalent global framework exists for complex biologics. Cross-referencing with a 2023 Lancet Diabetes & Endocrinology observational analysis (n=47 countries) shows that every 10% drop in GLP-1 list price expands treatment coverage by 4–7 percentage points among eligible adults, an effect magnified when biosimilar entry is synchronized. A separate 2024 WHO technical report on biologic regulatory convergence (non-randomized expert consultation) estimates that mutual-recognition agreements could reduce development costs by 25–40%, accelerating availability in markets like Nigeria and Indonesia where current rules mandate redundant local studies. These gaps compound real-world treatment shortfalls: U.S. Medicare data indicate only 12% of eligible type-2 diabetes patients receive GLP-1 therapy, with cost cited as the primary barrier. Harmonized standards would compress launch timelines, increase manufacturer competition, and transmit price reductions globally—precisely the mechanism that delivered trillions in generic savings over three decades.